Variation in serum urate levels in the absence of gout and urate lowering therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2520-1026
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Variation in serum urate levels in the absence of gout and urate lowering therapy ; volume:5 ; number:1 ; day:8 ; month:9 ; year:2021 ; pages:1-7 ; date:12.2021
BMC Rheumatology ; 5, Heft 1 (8.9.2021), 1-7, 12.2021
- Urheber
-
Shaffer, Andrew
Rahn, Elizabeth
Saag, Kenneth
Mudano, Amy
Gaffo, Angelo
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s41927-021-00202-6
- URN
-
urn:nbn:de:101:1-2021092620295685043579
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Shaffer, Andrew
- Rahn, Elizabeth
- Saag, Kenneth
- Mudano, Amy
- Gaffo, Angelo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Adherence with urate-lowering therapies for the treatment of gout
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
Urate (Urinverbindungen)
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
Factors associated with initiation and persistence of urate-lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
Urate (Urinverbindungen)
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
Factors associated with initiation and persistence of urate-lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
Urate (Urinverbindungen)
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age